The immuno-maintenance therapy of carilizumab was continued until the tumor progressed one year after the operation (new bone metastatic foci and suspected lung nodal foci increased in size, and tumor metastases were taken into consideration), and the genetic test showed mutations of EGFR and TP53, and the targeted therapy of gefitinib was given. This evidence concerns the gene EGFR and neoplasm.